09.09.14
Mazor Robotics Ltd. received China Food and Drug Administration (CFDA) approval of the company's Renaissance surgical guidance system for spine surgeries.
In addition to gaining the necessary regulatory approvals, the company’s distribution partner in China, Cicel, has coordinated seminars and hands-on-lab experiences in the United States for China’s leading spine surgeons to learn about the Renaissance system and its clinical benefits. Cicel is based in Beijing and has six other offices throughout China helping to establish relationships with surgeons, hospitals and other medical organizations.
“Receiving CFDA’s approval for marketing the Renaissance system in China is a significant achievement for Mazor, giving us access to a large and growing market opportunity,” said Ori Hadomi, CEO of Mazor, which is headquartered in Caesarea, Israel. “China continues to adopt proven and state-of-the-art technologies to offer better patient outcomes, so we believe Renaissance is well-positioned to gain market acceptance.
According to Hadomi, Cicel officials claim that the target market for Renaissance is in the hundreds of hospitals in China.
"Now, with the CFDA approval, our partner will initiate its marketing and sales process to introduce Renaissance to this important market," he said. "Cicel has the local market knowledge and expertise along with the sales, marketing and clinical organization to quickly raise awareness of the Renaissance system.”
Currently, Mazor has seven Renaissance systems installed throughout Asia in India, Hong Kong, Taiwan, Singapore, Vietnam and Australia.
According to the company, its robotics systems have been successfully used in the placement of more than 50,000 implants worldwide.
In addition to gaining the necessary regulatory approvals, the company’s distribution partner in China, Cicel, has coordinated seminars and hands-on-lab experiences in the United States for China’s leading spine surgeons to learn about the Renaissance system and its clinical benefits. Cicel is based in Beijing and has six other offices throughout China helping to establish relationships with surgeons, hospitals and other medical organizations.
“Receiving CFDA’s approval for marketing the Renaissance system in China is a significant achievement for Mazor, giving us access to a large and growing market opportunity,” said Ori Hadomi, CEO of Mazor, which is headquartered in Caesarea, Israel. “China continues to adopt proven and state-of-the-art technologies to offer better patient outcomes, so we believe Renaissance is well-positioned to gain market acceptance.
According to Hadomi, Cicel officials claim that the target market for Renaissance is in the hundreds of hospitals in China.
"Now, with the CFDA approval, our partner will initiate its marketing and sales process to introduce Renaissance to this important market," he said. "Cicel has the local market knowledge and expertise along with the sales, marketing and clinical organization to quickly raise awareness of the Renaissance system.”
Currently, Mazor has seven Renaissance systems installed throughout Asia in India, Hong Kong, Taiwan, Singapore, Vietnam and Australia.
According to the company, its robotics systems have been successfully used in the placement of more than 50,000 implants worldwide.